- Home
- GTES vs LGND Comparison
GTES vs LGND Comparison
Compare GTES & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTES | LGND |
|---|---|---|
| Founded | 1911 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.0B |
| IPO Year | 2017 | 1997 |
Fundamental Metrics
Financial Performance| Metric | GTES | LGND |
|---|---|---|
| Price | $24.91 | $307.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | $33.25 | ★ $344.25 |
| AVG Volume (30 Days) | ★ 1.6M | 193.7K |
| Earning Date | 10-30-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.73 | ★ 2886.36 |
| EPS | 0.90 | ★ 1.63 |
| Revenue | N/A | ★ $141,102,000.00 |
| Revenue This Year | $4.93 | $8.04 |
| Revenue Next Year | $4.99 | $31.71 |
| P/E Ratio | ★ $29.57 | $193.86 |
| Revenue Growth | N/A | ★ 29.48 |
| 52 Week Low | $20.88 | $175.89 |
| 52 Week High | $30.34 | $326.63 |
Technical Indicators
Market Signals| Indicator | GTES | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 55.78 |
| Support Level | $23.66 | $277.97 |
| Resistance Level | $26.97 | $318.30 |
| Average True Range (ATR) | 0.96 | 11.18 |
| MACD | -0.14 | 0.47 |
| Stochastic Oscillator | 15.03 | 73.31 |
Price Performance
Historical ComparisonAbout GTES Gates Industrial Corporation plc
Gates Industrial Corp Ltd operates as a manufacturer of application-specific fluid power and power transmission solutions. Its product portfolio includes engineered components used in power transmission and fluid power applications across a range of end markets and geographic regions.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.